Generation Bio Co. (GBIO)
After hours:
| Previous Close | 4.9400 |
| Open | 5.0000 |
| Bid | 4.6900 x 1100 |
| Ask | 4.6900 x 1000 |
| Day's Range | 4.6200 - 4.9400 |
| 52 Week Range | 3.9600 - 26.0700 |
| Volume | |
| Avg. Volume | 313,352 |
| Market Cap | 282.074M |
| Beta (5Y Monthly) | 1.95 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.2690 |
| Earnings Date | Nov 08, 2022 - Nov 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.75 |
- GlobeNewswire
Generation Bio to Present at the 2022 Jefferies Cell and Genetic Medicine Summit
CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that the company will participate in a fireside chat at the 2022 Jefferies Cell & Genetic Medicine Summit on Thursday, September 29th at 10:30 a.m. ET in New York. A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com.
- GlobeNewswire
Generation Bio Names Phillip Samayoa, Ph.D. Chief Strategy Officer
CAMBRIDGE, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced the promotion of Phillip Samayoa, Ph.D., to chief strategy officer. Dr. Samayoa has led strategy, corporate and portfolio development at Generation Bio since he joined the company in 2017, most recently serving as senior vice president. “Phillip has been instrumental in building a holistic strate
- Simply Wall St.
A number of insiders bought Generation Bio Co. (NASDAQ:GBIO) stock last year, which is great news for shareholders
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...
